GSTC (GlobeStar Therapeutics) Shiller PE Ratio: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlobeStar Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlobeStar Therapeutics  (OTCPK:GSTC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GlobeStar Therapeutics Shiller PE Ratio Related Terms


GlobeStar Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for GlobeStar Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlobeStar Therapeutics Shiller PE Ratio Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GSTC vs GBLX, ENDV, CNBX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, GlobeStar Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Shiller PE Ratio falls into.



GlobeStar Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GlobeStar Therapeutics's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, GlobeStar Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.0002/314.1750*314.1750
=-0.000

Current CPI (Jun. 2024) = 314.1750.

GlobeStar Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -3.000 238.343 -3.954
201409 -1.000 238.031 -1.320
201412 -1.000 234.812 -1.338
201503 -1.000 236.119 -1.331
201506 -0.760 238.638 -1.001
201509 -0.033 237.945 -0.043
201512 -0.020 236.525 -0.027
201603 -0.020 238.132 -0.026
201606 -0.005 241.018 -0.006
201612 -0.009 241.432 -0.011
201703 -0.005 243.801 -0.007
201706 -0.005 244.955 -0.006
201709 -0.022 246.819 -0.027
201712 -0.009 246.524 -0.012
201803 -0.001 249.554 -0.001
201806 -0.002 251.989 -0.002
201809 -0.003 252.439 -0.004
201812 -0.004 251.233 -0.006
201903 -0.002 254.202 -0.003
201906 0.000 256.143 0.000
201909 -0.016 256.759 -0.020
201912 -0.001 256.974 -0.001
202003 -0.001 258.115 -0.001
202006 -0.000 257.797 -0.000
202009 -0.000 260.280 -0.000
202012 -0.000 260.474 -0.000
202103 -0.002 264.877 -0.002
202106 -0.010 271.696 -0.011
202109 -0.008 274.310 -0.010
202112 -0.001 278.802 -0.001
202203 -0.001 287.504 -0.001
202206 -0.000 296.311 -0.000
202209 -0.000 296.808 -0.000
202212 -0.000 296.797 -0.000
202303 -0.000 301.836 -0.000
202306 -0.002 305.109 -0.002
202309 -0.000 307.789 -0.000
202312 -0.000 306.746 -0.000
202403 -0.000 312.332 -0.000
202406 -0.000 314.175 -0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlobeStar Therapeutics Business Description

Address 719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.